-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Lilly announced that its CDK4 and 6 inhibitors, Verzenio (abemaciclib), have been found to significantly prolong the lives of women with HR-, HER2-advanced breast cancer.
The drug is the first and only CDK4 and 6 inhibitors used in combination with fluovirus groups, and based on phase III MONARCH 2 studies, there is a significant statistical improvement in total survival rates in patients/post-menoanth and post-menoanthetic women who progress after endocrine therapy for cancer.
The analysis showed that the combined therapy met the secondary endpoint of its total survival rate. Previous MONARCH 2 studies have confirmed a significant improvement in statistically progress-free survival, with the main endpoint of the trial being used in more than 50 countries around the world as the basis for its approval of the programme. No new security signals were observed in the analysis of MONARCH 2, which is consistent with Verzenio's established security profile.
“ I believe we must continue to fight this devastating disease because women with metastasis breast cancer want to do everything they can to live a fuller life and serve those who need them most," said Anne White, Lilly's president of oncology research and development.
Anne continued, "While Verzenio has brought impressive benefits to progress-free survival, we are pleased that Verzenio is the first and only CDK4 and 6 inhibitor used in a joint way with the Fluvis group to significantly extend and extend the lifespan of post-menomaniotic and post-menomaniotic women."
Breast cancer is the most common cancer among women worldwide, with more than 2 million new cases diagnosed in 2018. Advanced breast cancer includes metastatic breast cancer, a cancer that spreads from breast tissue to other parts of the body, and advanced breast cancer, a local or regional cancer, which means that the cancer has grown outside the organs where it started but has not yet spread to other parts of the body.
Lilly plans to submit data to regulators and provide detailed data at a medical conference later this year. （cyy123.com）
